Prestige Consumer Healthcare Inc. $PBH Shares Sold by Clearbridge Investments LLC

Clearbridge Investments LLC cut its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 8.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,490 shares of the company’s stock after selling 10,220 shares during the period. Clearbridge Investments LLC owned 0.25% of Prestige Consumer Healthcare worth $7,186,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PBH. Massachusetts Financial Services Co. MA grew its stake in Prestige Consumer Healthcare by 10.2% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock worth $40,147,000 after purchasing an additional 60,496 shares in the last quarter. Nordea Investment Management AB grew its stake in Prestige Consumer Healthcare by 547.4% in the fourth quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock worth $37,811,000 after purchasing an additional 520,186 shares in the last quarter. Leeward Investments LLC MA grew its stake in Prestige Consumer Healthcare by 23.3% in the fourth quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock worth $23,894,000 after purchasing an additional 73,162 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Prestige Consumer Healthcare by 30.1% in the third quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock worth $28,656,000 after purchasing an additional 106,224 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in Prestige Consumer Healthcare by 1.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after purchasing an additional 21,085 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $49.09 on Thursday. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $87.12. The company has a market cap of $2.33 billion, a price-to-earnings ratio of 12.55, a price-to-earnings-growth ratio of 1.56 and a beta of 0.35. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57. The firm has a fifty day moving average of $52.42 and a 200-day moving average of $59.75.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. During the same period last year, the firm posted $1.32 EPS. The business’s revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the sale, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.40% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PBH shares. Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Canaccord Genuity Group dropped their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).